Subdural Hematoma After a Fall in an Elderly Patient Taking High-Dose Omega-3 Fatty Acids with Warfarin and Aspirin: Case Report and Review of the Literature

2007 ◽  
Vol 27 (1) ◽  
pp. 152-160 ◽  
Author(s):  
Elizabeth M McClaskey ◽  
Elizabeth Landrum Michalets
Keyword(s):  
Elderly Patient ◽  
Fatty Acids ◽  
Case Report ◽  
Subdural Hematoma ◽  
High Dose ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Review Of The Literature

scholarly journals Dose-response effects of omega-3 on platelet aggregation: an observational study

2018 ◽  
Vol 46 (12) ◽  
pp. 5074-5082 ◽  
Author(s):  
Thomas Kander ◽  
Erik Lindblom ◽  
Ulf Schött
Keyword(s):  
Fatty Acids ◽  
Platelet Aggregation ◽  
Healthy Volunteers ◽  
Dose Response ◽  
High Dose ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Positive Health ◽  
Inhibiting Effect

Objective This study aimed to evaluate the dose-response effects of supplemental omega-3 fatty acids on platelet function in healthy volunteers. Methods Twelve healthy volunteers ingested a normal supplemental dose of 1260 mg omega-3 fatty acids daily for 5 days, followed by a high dose of 2520 mg daily for another 5 days. Multiple electrode aggregometry (MEA) with four different agonists was used to measure platelet aggregation before and after the normal- and high-dose regimes. In vitro spiking using physiological doses of omega-3 fatty acids was also performed to determine whether MEA is capable of detecting a platelet-inhibiting effect due to omega-3 fatty acids. Results There were no differences in platelet aggregation measured by the MEA assay in healthy volunteers after intake of either the normal or high dose of omega-3 fatty acids. In the in vitro experiment, a platelet-inhibiting effect of omega-3 fatty acids was shown by an arachidonic acid agonist in MEA . Conclusions Supplemental omega-3 fatty acids do not evoke their positive health effects through inhibition of platelet aggregation measurable with MEA.

scholarly journals Capgras syndrome in substance-induced psychosis

2018 ◽  
Vol 10 (2) ◽  
Author(s):  
Bharat R. Sampathi ◽  
Anna Sofine ◽  
John Alvarez ◽  
Robert G. Bota
Keyword(s):  
Fatty Acids ◽  
Substance Use ◽  
Case Report ◽  
Family Member ◽  
Delusional Disorder ◽  
Psychiatric History ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Capgras Syndrome ◽  
Oxidative Effects

Capgras Syndrome is a subcategory of delusional disorder. People affected by this syndrome believe that a close associate such as a friend or family member has been replaced by an identical imposter. This case report describes a 23-year-old woman with no prior psychiatric history, whom developed Capgras syndrome, via folie a deux, in the setting of poly-substance use. In this patient, a combination of Aripiprazole 10 mg daily and Escitalopram 10 mg daily were effective in resolving symptoms. Clonazepam was utilized for anxiety and Omega-3 fatty acids 1 g for anti-oxidative effects. Further studies are needed to investigate the effects of a variety of causes and treatments for Capgras Syndrome.

scholarly journals Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women

2015 ◽  
Vol 8 (10) ◽  
pp. 912-921 ◽  
Author(s):  
Carol J. Fabian ◽  
Bruce F. Kimler ◽  
Teresa A. Phillips ◽  
Jessica A. Box ◽  
Amy L. Kreutzjans ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fatty Acids ◽  
Pilot Study ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Premenopausal Women ◽  
High Dose ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Risk Biomarkers

Gastrointestinal Bleeding After High Intake of Omega-3 Fatty Acids, Cortisone and Antibiotic Therapy: A Case Study

2014 ◽  
Vol 24 (3) ◽  
pp. 253-257 ◽  
Author(s):  
Paraskevi Detopoulou ◽  
Vasilios Papamikos
Keyword(s):  
Fatty Acids ◽  
Previous History ◽  
High Dose ◽  
Present Observation ◽  
Protective Effects ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Animal Data ◽  
Gastrointestinal Problems ◽  
Amateur Athlete

Omega-3 fatty acids exert a plethora of physiological actions including triglycerides lowering, reduction of inflammatory indices, immunomodulation, anti- thrombotic effects and possibly promotion of exercise performance. Their use is widespread and for commonly ingested doses their side- effects are minimal. We report a case of a 60y amateur athlete who consumed about 20 g omega-3 fatty acids daily from supplements and natural sources for a year. After the intake of cortisone and antibiotics he presented duodenum ulcer and bleeding although he had no previous history of gastrointestinal problems. Although several animal data support gastro-protective effects of omega-3 fatty acids in the present case they were not able to prevent ulcer generation. The present observation may be explained by (i) the high dose of omega-3 fatty acids and their effect on bleeding, (ii) the fact that cortisone increases their oxidation and may render them proinflammatory, (iii) other antithrombotic microconstituents included in the consumed cod-oil and/or the diet of the subject and (iv) the differences in the coagulation and fibrinolytic systems of well- trained subjects. Further studies are needed to substantiate any possible interaction of cortisone and omega-3 fatty acids in wide ranges of intake.

scholarly journals Refractory Cutaneous IgA Vasculitis Treated with Omega-3 Fatty Acids

2016 ◽  
Vol 8 (3) ◽  
pp. 333-340 ◽  
Author(s):  
Maria A. Barnadas ◽  
Montserrat M. Díaz Encarnación
Keyword(s):  
Fatty Acids ◽  
Mycophenolate Mofetil ◽  
Case Report ◽  
Docosahexaenoic Acid ◽  
Therapeutic Strategies ◽  
Iga Vasculitis ◽  
Benzathine Penicillin ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
History Of

Background: Omega-3 fatty acids (O3FA) have been used to treat IgA nephropathy (IgAN) but not cutaneous IgA vasculitis (IgAV). Case Report: A 47-year-old female was referred for cutaneous vasculitis. She had a 24-year history of flares of palpable purpura, arthralgia associated with hematuria, and proteinuria. We diagnosed cutaneous IgAV associated with IgAN. We administered prednisone at doses ranging from 10 to 45 mg/day to control the flares. To reduce prednisone exposure, different therapeutic strategies (colchicine, diphenhydramine, hydroxyzine, azathioprine, benzathine penicillin, and mycophenolate mofetil) were applied without success. After 11 years, therapy with O3FA capsules containing 460 mg eicosapentaenoic acid and 380 mg of docosahexaenoic acid t.i.d. was introduced, allowing the prednisone to be stopped 2 years later. When the dose of O3FA was decreased to 1 capsule on alternate days, the cutaneous flares reappeared, but they were again controlled when the patient took 1 O3FA capsule daily. Conclusions: O3FA can be useful to control cutaneous IgAV.

scholarly journals The journey of omega-3 fatty acids in cardiovascular medicine

2020 ◽  
Vol 22 (Supplement_J) ◽  
pp. J49-J53
Author(s):  
Roberto Ferrari ◽  
S Censi ◽  
P Cimaglia
Keyword(s):  
Fatty Acids ◽  
Cardioprotective Effect ◽  
European Medicines Agency ◽  
High Dose ◽  
Antiarrhythmic Action ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Cardiac Events ◽  
Omega 3 Fatty Acid ◽  
Adverse Cardiac Events

Abstract In subjects with cardiovascular risk factors or in patients in need of secondary prevention, hypertriglyceridemia is a well-defined risk factor for adverse cardiac events. Drugs containing n-3 polyunsaturated fatty acids (n-3 PUFAs) are approved for treatment of hypertriglyceridemia. In 1999, a cardioprotective effect in post infarct patients was suggested by a large multicentre study, the GISSI prevention trial. The hypothesized mechanism of action was an antiarrhythmic action leading to reduction of the sudden death. However, such a cardioprotective effect of n-3 PUFAs has not been straightforward like for other cardiovascular drugs such as aspirin, statins or ACE inhibitors. On the contrary, it has been a long journey with several ups and downs. Recently, the European Medicines Agency (EMA) has not confirmed the risk benefit of low dose of n-3 PUFA in preventing outcomes after a myocardial infarction. Since the EMA decision, the use of a high dose (4g daily) of pure and stable EPA in a multicentre, international trial, the REDUCE-IT study showed a clear cardiovascular event reduction which was not confirmed in another trial, the STRENGTH study, which utilized 4g daily of an EPA+DHA mixture. It follows that the OMEGA-3 fatty acid story seems to be endless and the last word on cardiovascular benefits cannot be pronounced. We report a brief narrative of an entire journey from the beginning to nowadays.

Sign in / Sign up

Export Citation Format

Share Document